Shanghai Junshi Biosciences Co (1877) Q3 2025 earnings summary

Executive summary

• Achieved strong international expansion for toripalimab, now approved in over 40 countries and regions, with significant regulatory milestones in the US, EU, and other major markets.

• Operating income for the first three quarters of 2025 reached RMB 1.81 billion, up 42.06% year-over-year, driven by strong sales of commercialized drugs, especially toripalimab injection, which saw a 40% increase in domestic sales revenue to RMB 1.495 billion.

• Net loss attributable to shareholders narrowed to RMB 595.7 million for the first three quarters, a significant improvement from the prior year, reflecting enhanced expense management and operational efficiency.

• Multiple products, including MINDEWEI and JUNMAIKANG, received expanded approvals and broader NRDL coverage in China.

• Cash and bank balances plus financial assets for trading totaled RMB 3.27 billion at period end, indicating robust liquidity.

Financial highlights

• Total operating income for Q1-3 2025 reached RMB 1,806 million, up 42.06% year-over-year.

• Domestic sales revenue of PD-1 products was RMB 1,495 million, up 40% year-over-year.

• Total operating expenses increased 9.38% year-over-year to RMB 2,473 million.

• Net loss attributable to shareholders for Q3 was RMB 183.0 million; basic and diluted EPS were both -0.18 RMB.

• For the first three quarters, net loss attributable to shareholders was RMB 595.7 million, with basic and diluted EPS at -0.60 RMB.

Outlook and guidance

• Continued focus on international expansion and regulatory submissions in new markets.

• The company plans to accelerate R&D and global commercialization, focusing on pipeline advancement and operational efficiency to drive future revenue growth.

• Multiple late-stage clinical trials and pivotal studies expected to yield data in 2025.

• Ongoing investments in R&D and production capacity to support future growth.